India aims to create a domestic “Big Four” in audit and advisory by easing advertising rules, allowing multi-disciplinary partnerships, and…
96% jump in maximum salary for PGP 2025 batch.
The shift towards a more flexi workforce over the next 5 years will be driven by the sustained adoption of…
As per the ratings agency, the API capacities are largely fungible in nature and domestic companies might be able to…
The note said that even though the government is actively working towards amending the relevant acts and regulations to support…
The startups said that the terms of reference of the agency that will be tasked to do the market study…
The scheme, announced in August 2023, is aimed at fostering innovation in the pharmaceutical and medical devices sectors, with a total financial…
The Competition Commission of India (CCI) is studying whether Google and Microsoft’s bundling of AI tools with office suites violates…
NFRA-2 is an annual return that statutory auditors of listed and specified classes of unlisted companies must file with the…
CII is finalizing a national framework for Global Capability Centers (GCCs) to boost growth in tier-II and III cities. The…
The central drugs regulator has ordered manufacturers and importers of Class C and D medical devices to update their inventories…
The cabinet has cleared a Rs 4,447 crore greenfield highway corridor in Bihar and a Rs 3,169 crore rail line…
Govt extends fast-track merger route to more firms, easing M&A approvals and boosting reverse flipping of startups shifting domicile to…
Look-back period for ‘avoidance transactions’ to be indefinite
The government’s IBC Amendment Bill 2025 introduces Section 164A, empowering resolution professionals to reverse fund transfers made before personal insolvency.…
In a significant move, the government has reduced GST on all pharmaceutical formulations from 12% to 5% and exempted 33…
The National Institutional Ranking Framework (NIRF) 2025 results have been announced, with IIT Madras, IISc, and IIT Bombay securing the…
GST Council may cut rates on 36 critical drugs and 25 medical devices, with cancer and rare disease therapies set…
